KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31

KYNTRA BIO, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$5.28+0.43 (+8.87%)

Close on Oct 19, 2026

Market cap: $21.37M
P/E (TTM): 0.1
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$6.44MFY2025, -20.6% a year since FY2013

Where these numbers come from

Parsed from the XBRL in Kyntra Bio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Aug 11, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KYNB.

Revenue growth-37.1% · median 12.8%

Operating margin-1089.8% · median -467.9%

Net margin3967.8% · median -611.5%

Company	Revenue	Growth
EMMA	$15.53M	–
BOLT	$4.70M	+12.8%
KYNB	$4.62M	-37.1%
ENSC	$4.50M	-39.3%
CNTB	$2.95M	+50.3%
TRAW	–	–

Company

Next earnings (est.): Nov 9, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 34
Held by institutions: 24.7%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 921299

Advertisement
300 × 250